Form 4: Mineralys Therapeutics CMO Executes Stock Option Plan

Chief Medical Officer David Malcom Rodman exercised and sold shares of Mineralys Therapeutics under a Rule 10b5-1 plan.

Summary

• David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., exercised stock options for 2,170 shares at $16.00 and 6,349 shares at $1.08.
• Following the exercises, the reporting person sold an equivalent number of shares (8,519 total) on the open market.
• The sales were executed at weighted-average prices of $25.00 and $23.9252 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive financial management rather than a change in company outlook.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating the sales were not based on sudden non-public information.
• The executive maintains a significant remaining beneficial ownership of 63,443 shares of common stock.

Negatives

• The executive reduced their direct holdings through the sale of 8,519 shares.

Risks

• Future stock price volatility may impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the reporting person.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for executives in the biotechnology sector to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for biotech executives to avoid potential insider trading allegations.
• The volume of shares sold is consistent with typical executive compensation liquidation patterns in mid-cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders as the sales were executed through a pre-arranged plan.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, Insider Trading, Form 4, Stock Options, Rule 10b5-1